Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of futibatinib in patients with specific FGFR aberrations
jRCT2080225216Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of futibatinib in Nonhematologic neoplasms, gastric cancer (GC), esophagogastric junction cancer and 1 more (3 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Started Jun 2020; status: completed.
02
Drugs
futibatinib
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)esophagogastric junction cancermyeloid/lymphoid neoplasms (MLNs)
Beyond the preview
Go deeper on jRCT2080225216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225216.